Treatment of metastatic renal cell carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 1, 2009, Pages 11-25

  Reeves, David J ^a   Liu, Chin Y ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Interferon; Interleukin 2; Renal cell carcinoma; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID; DESIPRAMINE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; HISTAMINE H1 RECEPTOR ANTAGONIST; IRINOTECAN; KETOCONAZOLE; MEDROXYPROGESTERONE; PARACETAMOL; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; RIFAMPICIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THEOPHYLLINE; UGT1A1; UNCLASSIFIED DRUG; VINBLASTINE; WARFARIN; ZIDOVUDINE;

ADD ON THERAPY; ADRENAL DISEASE; ALKALINITY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BEDTIME DOSAGE; BLEEDING; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; CHILL; CLEAR CELL CARCINOMA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CYTOPENIA; DEPRESSION; DIAPHORESIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALAISE; MEDICAL SOCIETY; METASTASIS; MONOTHERAPY; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHRECTOMY; NEUROLOGIC DISEASE; NEUTROPENIA; OPTIMAL DRUG DOSE; PAIN; PANCREATITIS; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RIGOR; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SYNCOPE; TASTE DISORDER; THORAX PAIN; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TORSADE DES POINTES; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION; WHEEZING; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 67349281283     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0983-z     Document Type: Short Survey

References (61)

1. A Jemal R Siegel E Ward 2008 Cancer Statistics, 2008 CA Cancer J Clin 58 71 96
2. National Cancer Care Network (2008) Kidney cancer V.1.2008. www.nccn.org/professionals/physician-gls/PDF/kidney.pdf . Accessed 1 March 2008
3. HL Kim D Seligson X Liu 2005 Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma J Urol 173 1496 1501 (Pubitemid 40524757)
4. A Mancuso CN Sternberg 2005 New treatments for metastatic kidney cancer Can J Urol 12 Suppl 1 66 70
5. HT Cohen FJ McGovern 2005 Renal-cell carcinoma N Engl J Med 353 2477 2490 (Pubitemid 41770167)
6. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch (2008) Surveillance, Epidemiology and End Results (SEER) Program Stat Database. www.seer.cancer.gov . Accessed 3 Mar 2008
7. RJ Motzer M Mazumdar J Bacik 1999 Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 2530 2540 (Pubitemid 29368255)
8. RJ Motzer J Bacik M Mazumdar 2004 Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience Clin Cancer Res 10 6302S 6303S (Pubitemid 39287482)
9. A Yagoda B Abi-Rached D Petrylak 1995 Chemotherapy for advanced renal-cell carcinoma: 1983-1993 Semin Oncol 22 42 60
10. G Fyfe RI Fisher SA Rosenberg 1995 Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 688 696
11. RI Fisher SA Rosenberg G Fyfe 2000 Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am 6 Suppl 1 S55 S57 (Pubitemid 30117639)
12. Product information (2007) Proleukin (aldesleukin). Novartis Pharmaceuticals Corporation, East Hanover
13. JC Yang RM Sherry SM Steinberg 2003 Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 3127 3132 (Pubitemid 46606294)
14. DF Mcdermott MM Regan JI Clark 2005 Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 133 141 (Pubitemid 41702632)
15. SD Fossa 2000 Interferon in metastatic renal cell carcinoma Semin Oncol 27 187 193 (Pubitemid 30205373)
16. LM Minasian RJ Motzer L Gluck 1993 Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up J Clin Oncol 11 1368 1375 (Pubitemid 23199143)
17. JR Quesada 1989 Role of interferons in the therapy of metastatic renal cell carcinoma Urology 34 Suppl 4 80 83 (Pubitemid 19256922)
18. S Pyrhonen E Salminen M Ruutu 1999 Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer J Clin Oncol 17 2859 2867 (Pubitemid 29415245)
19. A Ritchie G Griffiths M Parmar 1999 Interferon-α and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial Lancet 353 14 17 (Pubitemid 29037696)
20. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T (2004) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (3):CD001425. doi: 10.1002/14651858.CD001425.pub2
21. Product information (2008) Intron-A (interferon-α2b). Shering Corporation, Kenilworth
22. A Mancuso CN Sternberg 2006 New treatment approaches in metastatic renal cell carcinoma Curr Opin Urol 16 337 341 (Pubitemid 44231708)
23. Product information (2008) Nexavar (sorafenib). Bayer Pharmaceuticals Corporation, West Haven
24. B Escudier T Eisen WM Stadler 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 (Pubitemid 46089673)
25. JA Gollob WK Rathmell TM Richmond 2007 Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 3288 3295 (Pubitemid 47325614)
26. CW Ryan BH Goldman PN Lara Jr 2007 Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 3296 3301 (Pubitemid 47325615)
27. Szczylik C, Demkow T, Staehler M et al (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25(Suppl 18) (abstract 5025)
28. RJ Motzer TE Hutson P Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 (Pubitemid 46089672)
29. Figlin R, Hutson TE, Tomczak P et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26(Suppl 18) (abstract 5024)
30. RJ Motzer MD Michaelson BG Redman 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 (Pubitemid 46630489)
31. RJ Motzer MD Michaelson J Rosenberg 2007 Sunitinib efficacy against advanced renal cell carcinoma J Urol 178 1883 1887 (Pubitemid 47538608)
32. G Hudes M Carducci P Tomczak 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 (Pubitemid 46849157)
33. B Escudier A Pluzanska P Koralewski 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 (Pubitemid 350296300)
34. Rini BI, Halabi S, Rosenberg J et al (2008) A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. In: Genitourinary cancer symposium, American Society of Clinical Oncology, San Francisco (abstract 350). http://www.asco.org/ ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst-detail- view&confID=54&abstractID=20357 . Accessed 17 Apr 2008
35. JC Yang L Haworth RM Sherry 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 (Pubitemid 36910021)
36. Product information (2008) Sutent (sunitinib). Pfizer, Inc, New York
37. D Pouessel S Culine 2008 High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor Eur Urol 53 376 381 (Pubitemid 350296582)
38. Porta C, Paglino C, Imarisio I (2008) Re: Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor. Eur Urol 53:1092-1093 (comment)
39. S Wu JJ Chen A Kudelka 2008 Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 117 123
40. TF Chu MA Rupnick R Kerkela 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2011 2019 (Pubitemid 350236338)
41. CH Yang WC Lin CK Chuang 2008 Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy Br J Dermatol 158 592 596
42. SE Rosenbaum S Wu MA Newman 2008 Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib Support Care Cancer 16 557 566
43. Product information (2007) Torisel (temsirolimus). Wyeth Pharmaceuticals Inc, Philadelphia
44. Product information (2008) Avastin (bevacizumab). Genentech, Inc, San Francisco
45. ® (bevacizumab) and sunitinib malate. http://www.fda.gov/medwatch/safety/2008/ MAHA-DHCP.pdf . Accessed 1 Sept 2008
46. I Tamaskar JA Garcia P Elson 2008 Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy J Urol 179 81 86 (Pubitemid 350216728)
47. Drabkin HA, Figlin R, Stadler WM et al (2007) The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients with prior bevacizumab treatment. J Clin Oncol 25(Suppl 18) (abstract 5041)
48. George DJ, Michaelson MD, Rosenberg J et al (2007) Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 25(Suppl 18) (abstract 5035)
49. Feldman DR, Ginsberg MS, Baum C et al (2008) Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 26(Suppl 18) (abstract 5100)
50. Sosman JA, Flaherty KT, Atkins MB et al (2008) Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 26(Suppl 18) (abstract 5011)
51. Merchan JR, Liu G, Fitch T et al (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 25(Suppl 18) (abstract 5034)
52. MJ Ratain T Eisen WM Stadler 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 (Pubitemid 46630627)
53. TK Choueiri A Plantade P Elson 2008 Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 127 131
54. Stadler WM, Figlin R, Ernstoff MS et al (2007) The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients with non-clear cell renal cell carcinoma. J Clin Oncol 25(Suppl 18) (abstract 5036)
55. Dutcher JP, Wilding G, Hudes GR et al (2008) Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 26(Suppl 18) (abstract 5127)
56. Rini BI, Wilding G, Hudes G et al (2007) Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25(Suppl 18) (abstract 5032)
57. Hutson TE, Davis ID, Machiels JP et al (2007) Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 25 (Suppl 18) (abstract 5031)
58. Ravaud A, Gardner R, Hawkins R et al (2006) Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma. J Clin Oncol 24(Suppl 18) (abstract 4502)
59. RJ Motzer B Escudier S Oudard 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial Lancet 372 449 456
60. LaGow B (ed) (2008) Red book. Thompson Healthcare, Montvale
61. Klatte M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2007) Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma. J Clin Oncol 25 (Suppl 18) (abstract 5112)